CX Institutional’s Steris STE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$251K Buy
1,191
+11
+0.9% +$2.36K 0.01% 689
2026
Q1
$261K Buy
1,180
+3
+0.3% +$734 0.01% 653
2025
Q4
$298K Buy
1,177
+176
+18% +$44.2K 0.01% 587
2025
Q3
$248K Buy
1,001
+39
+4% +$9.34K 0.01% 624
2025
Q2
$231K Buy
962
+31
+3% +$7.22K 0.01% 581
2025
Q1
$211K Buy
+931
New +$205K 0.01% 589
2022
Q3
Sell
-272
Closed -$56K 1045
2022
Q2
$56K Buy
+272
New +$61.3K ﹤0.01% 655
2021
Q4
Sell
-260
Closed -$53K 821
2021
Q3
$53K Sell
260
-11
-4% -$2.35K ﹤0.01% 567
2021
Q2
$56K Buy
271
+33
+14% +$6.64K ﹤0.01% 547
2021
Q1
$45K Buy
238
+22
+10% +$4.08K ﹤0.01% 511
2020
Q4
$41K Buy
216
+7
+3% +$1.31K ﹤0.01% 476
2020
Q3
$37K Buy
209
+88
+73% +$14.1K ﹤0.01% 441
2020
Q2
$19K Buy
121
+6
+5% +$914 ﹤0.01% 454
2020
Q1
$16K Buy
115
+17
+17% +$2.54K ﹤0.01% 407
2019
Q4
$15K Hold
98
﹤0.01% 386
2019
Q3
$14K Buy
98
+39
+66% +$5.83K ﹤0.01% 422
2019
Q2
$9K Buy
+59
New +$7.88K ﹤0.01% 510

Other funds holding STE

CX Institutional's STE Position: Q2 2026 in Review

CX Institutional increased its Steris (STE) stake by 0.93% in Q2 2026, buying an estimated $2.36K and bringing the position to 1,191 shares worth $251K. The position accounts for 0.01% of the portfolio, ranked #689.

CX Institutional first reported a position in STE in Q2 2019 and has held it in 17 quarters since. The position peaked at $298K in Q4 2025. 137 funds tracked by Wall St. Rank hold STE as of Q2 2026.

  • CX Institutional held 1,191 shares of Steris worth $251K as of Q2 2026.
  • CX Institutional bought 11 Steris shares in Q2 2026, an estimated $2.36K.
  • Steris made up 0.01% of CX Institutional's portfolio in Q2 2026, its #689 holding.
  • CX Institutional first reported a position in Steris in Q2 2019 and has held it in 17 quarters since.
  • CX Institutional's Steris position peaked at $298K in Q4 2025.
  • 137 funds tracked by Wall St. Rank held Steris as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.